MannKind Corporation has received a grant from Breakthrough T1D to support the INHALE-1 clinical study of Afrezza, its ultra-rapid-acting inhaled insulin, in newly diagnosed paediatric type 1 diabetes patients aged 10 to under 18 years. The external funding follows May 2026 FDA approval of Afrezza for children aged six and older. Together, these developments position paediatric Afrezza as both a growth opportunity and a test of whether MannKind can overcome awareness and reimbursement challenges that have limited adult adoption. Analysts project MannKind's revenue to reach $554.4 million by 2029, requiring 15.4% annual growth. However, bearish estimates suggest only 7.4% annual revenue growth to roughly $447 million. The grant helps de-risk paediatric development but doesn't materially change near-term risks around high spending and limited diversification.

Syntax Bio pairs with Mayo Clinic on stem-cell pancreatic cell therapies for type 1 diabetes. The partners seek to define and subsequently develop an allogeneic pancreatic beta cell therapy based on patient needs. June 9, 2026 Content Marketing Editor Editor's Take: Mayo Clinic's expertise in pancreatic biology will be a boost to regulatory-enabling studies and early clinical development. Syntax Bio, a Chicago-based synthetic biology company, launched an R&D collaboration with Mayo Clinic, advancing therapies for type 1 diabetes. Namely, the teams will target stem cell-derived pancreatic cell therapies, hoping to define and develop an allogeneic beta cell therapy. This therapy will then ideally be used to treat insulin-dependent diabetes, based on patient needs. Syntax Bio's platform. To accomplish this, Syntax Bio is deploying its proprietary platform, Cellgorithm, to guide induced pluripotent stem cells into beta cells. The technology of the platform simplifies stem cell differentiation by programming gene activation sequences necessary to create specific cell types. Syntax Bio says Cellgorithm has demonstrated an ability to generate target cell types in weeks or days, versus months. The company adds this also reduces the need for repetitive manual interventions. Recently, Syntax Bio received a grant award from Breakthrough T1D for purposes of advancing pancreatic beta cell therapy. How Mayo Clinic helps. Mayo Clinic's role in the collaboration will be providing expertise in pancreatic biology and functional testing in preclinical diabetes models. These capabilities will support regulatory-enabling studies and, eventually, early clinical development. There are practical challenges, the two parties say, to developing pancreatic cell therapies that this collaboration aims to solve. Included among these: ensuring correct cell type, proper cell function, consistent production, and manufacturing at scale. Working in rapid development cycles, the teams will use results from functional testing to improve cell identity, maturity, and performance. Unmet needs in type 1 diabetes. Syntax Bio CEO John Craighead commented on what to expect. "The collaboration reflects our belief that regenerative medicine must start with precise control over cell identity and function," Craighead said. "We aim to accelerate development of a next-generation cell therapy with transformative real-world benefits for patients with type 1 diabetes." Programs developed in the collaboration, meeting certain milestones, may advance through other biopharmaceutical partnerships to support development and potential testing.

Breakthrough T1D and Sub-Zero Group Foundation announce national partnership to support Type 1 Diabetes research. Jun 02, 2026, 11:39 ET NEW YORK and MADISON, Wis., June 2, 2026 /PRNewswire/ - Breakthrough T1D, formerly JDRF, the leading global type 1 diabetes research and advocacy organization, and the Sub-Zero Group Foundation, the philanthropic arm of Sub-Zero Group, manufacturer of Sub-Zero, Wolf, and Cove luxury appliances, proudly announce a new national partnership that will support Breakthrough T1D's mission to accelerate life-changing breakthroughs to cure, prevent, and treat type 1 diabetes and its complications. The partnership represents deepened engagement between the two organizations and a shared focus on type 1 diabetes awareness and research. "Breakthrough T1D is thrilled to welcome the Sub-Zero Group Foundation as a national partner and express our gratitude for their commitment to our mission," said Brett Collins, Breakthrough T1D vice president of corporate and institutional giving. "Sub-Zero's history of innovation aligns with Breakthrough T1D's focus on accelerating type 1 diabetes breakthroughs, with both rooted in improving the lives of those with type 1 diabetes as we drive toward cures for the disease. Partners like Sub-Zero are an essential part of the work we do every day to drive the progress that will make our mission possible." The Sub-Zero Group Foundation's philanthropic efforts are driven by the family-centric values that have been at the core of the organization since Sub-Zero's founding in 1945. At the heart of the partnership with Breakthrough T1D is the alignment with the Foundation's mission pillar focused on type 1 diabetes. Sub-Zero's history in refrigeration begins with type 1 diabetes, when company founder Westye F. Bakke sought to develop a reliable way to store his young son's insulin. This personal drive has fueled the organization's decades-long commitment to giving back. "Type 1 diabetes has been part of our story since the very beginning of Sub-Zero," said Jim Bakke, President and Chief Executive Officer of Sub-Zero Group. "What started as my grandfather's determination to care for his son grew into a company built on reliability, innovation, and purpose. Through the Sub-Zero Group Foundation, we are proud to deepen our partnership with Breakthrough T1D and support the critical research and advancements that give families hope for better treatments and, ultimately, cures." The contributions of national partners like the Sub-Zero Group Foundation help fund research that is advancing early detection of type 1 diabetes as well as the development of disease-modifying therapies that can change the course of T1D, technology to help with day-to-day T1D management, treatments that address complications of T1D, and cell therapies that may one day cure the disease. About Breakthrough T1D, Formerly JDRF As the leading global type 1 diabetes research and advocacy organization, Breakthrough T1D helps make everyday life with type 1 diabetes better while driving toward cures. We do this by investing in the most promising research, advocating for progress by working with government to address issues that impact the T1D community, and helping educate and empower individuals facing this condition. About Sub-Zero Group Foundation The Sub-Zero Group Foundation - formerly known as the Sub-Zero Wolf Foundation - is an independent, nonprofit philanthropic organization launched in 1997. Having invested more than $4M in local community organizations, the Foundation's mission is to foster innovation in the food ecosystem that increases community access to quality foods and invests in organizations that contribute to lifelong health. The focus areas of funding include juvenile diabetes, food security and community centers in Madison, Wisconsin and the greater Phoenix, Arizona area. About Type 1 Diabetes (T1D) T1D is an autoimmune condition that causes the pancreas to make very little insulin or none at all. This leads to dependence on insulin therapy and the risk of short and long-term complications, which can include highs and lows in blood sugar; damage to the kidneys, eyes, nerves, and heart; and even death. Globally, it impacts 9.5 million people. Many believe T1D is only diagnosed in childhood and adolescence, but diagnosis in adulthood is common and accounts for nearly 50% of all T1D diagnoses. The onset of T1D has nothing to do with diet or lifestyle. While its causes are not yet entirely understood, scientists believe that both genetic factors and environmental triggers are involved. There is currently no cure for T1D. SOURCE Breakthrough T1D, Formerly JDRF